On February 6, 2024, Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) that is strategically part of the University of Wisconsin (UW) Madison, announced a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. Through this collaboration, Waisman Biomanufacturing will incorporate RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services into its portfolio of biologics manufacturing services, expanding Waisman Biomanufacturing’s capabilities for the production of advanced therapies for clinical trials. Together, Waisman Biomanufacturing and RoosterBio deliver an end-to-end solution for the development and manufacturing of cell- and exosome-based therapeutics, including the critical raw materials, expert process development in both 2D and 3D systems, advanced analytical characterization, regulatory support packages, and proven cGMP manufacturing capabilities. Advanced therapy developers in both industry and academia can now accelerate and de-risk their progression into clinical trials by leveraging this new strategic collaboration.
Login Or Register To Read Full Story